CEO buying at Kane Biotech (KNE)

CEO buying at Kane Biotech (V:KNE)

Marc Edwards, CEO and Director, acquired 1,746,000 Common Shares on a direct ownership basis at prices ranging from $0.070 to $0.090 between October 25th and October 31st, 2018. This represents a $139,845 investment into the company's shares and an account share holdings change of greater than 100%.

Kane Biotech is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products that prevent and remove microbial biofilms. The Company's technologies include DispersinB, AloSera, Aledex, Strix NB, bluestem and KBI Disinfectant. It is focused on the companion animal market with Strix NB brand for the veterinary segment and bluestem brand for the pet over the counter (OTC) retail market. The Company markets its oral care technology into the Canadian pet specialty market under the bluestem brand. It has over 100 pet specialty stores in Canada, which are engaged in selling the bluestem oral health products. It has various formulations in development, including formulations with antibiotics and the antibiofilm enzyme beta-N-Acetylglucosaminidase and antibiofilm-antimicrobial formulations for both the veterinary and human markets. It is focused on the development of oral care spray formulation and a water additive powder formulation. Kane Biotech Inc. (KNE) has a high amount of executive buying compared to its micro-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $139,845.